Ayu Life Sciences, an India-based medical devices and cell therapy company, announced plans to establish a new AED33 million ($9 million) advanced manufacturing facility at Jebel Ali Free Zone (Jafza).
The new facility is billed as the first of its kind in the region. The 13,500 square metre facility will focus on the production of next-generation wound care solutions and surgical treatments, designed to meet the growing global demand for high-quality, sustainable healthcare products.
India’s Ayu expands globally
Dr. Rajan Datt, Managing Director of Ayu Life Sciences, said the company is excited to announce the new facility in Jafza, marking a major milestone for it.
“We look forward to breaking ground on this new facility and extending the reach of our flagship products like Velgraft, Velvert, and VelNez to more patients in the Middle East and around the globe,” he said.
Abdulla Al Hashmi, Chief Operating Officer Parks & Zones, DP World GCC, said Jafza’s manufacturing infrastructure and strategic connectivity make it the ideal launchpad for innovators like Ayu Life Sciences.
“This facility reinforces Dubai’s growing role as a global hub for the healthcare and advanced medical manufacturing sectors,” he said.
The launch comes amid a surge in demand for artificial skin, with the market projected to grow from $3.1 billion in 2024 to $5.3 billion by 2032.
The facility will be developed in two phases, with Phase 1 set to go live by late-2025, and full completion by 2027.
It will produce Ayu Life Sciences’ flagship products, including Velgraft, an artificial skin substitute designed for scar-free healing and tissue regeneration, Velvert, a natural antimicrobial wound care dressing formulated to accelerate healing and prevent infections, and VelNez, a nasal and ear dressing that enhances patient comfort and post-surgical recovery.
These solutions are backed by a portfolio of 22 global patents and developed using eco-friendly materials and natural components to minimise environmental impact.
The company currently exports from its Delhi facility to over 20 markets across North America, Europe, Asia, Australia, Africa, and the Middle East.
In addition to advanced wound care, Ayu Life Sciences is progressing in the field of regenerative medicine.
Clinical trials are underway for a novel therapy using cells similar to those in the pancreas to regulate blood sugar for patients with Type 1 diabetes, and for Velnerve, a solution for peripheral nerve injuries.
With Jafza already home to over 800 manufacturing companies from 75 countries, Ayu Life Sciences joins a thriving ecosystem of global innovators.
Follow us on
